ERBB2 and breast cancer: T-DXd would be cost-effective if its price were reduced to $17.00/mg, $17.13/mg, and $14.07/mg at a WTP threshold of $50,000/QALY for all HER2-low advanced BC and HER2-advanced BC, respectively.